Galectin Therapeutics
GALT
55 hedge funds and large institutions have $15.2M invested in Galectin Therapeutics in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 20 closing their positions.
118% more call options, than puts
Call options by funds: $759K | Put options by funds: $348K
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
0.05% more ownership
Funds ownership: 12.29% → 12.35% (+0.05%)
21% less funds holding
Funds holding: 70 → 55 (-15)
46% less capital invested
Capital invested by funds: $28.2M → $15.2M (-$13.1M)
65% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$586K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$198K |
| 3 |
Millennium Management
New York
|
+$158K |
| 4 |
SF
Synovus Financial
Columbus,
Georgia
|
+$137K |
| 5 |
Morgan Stanley
New York
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
-$529K |
| 2 |
HF
HRT Financial
New York
|
-$311K |
| 3 |
Capstone Investment Advisors
New York
|
-$164K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$121K |
| 5 |
CF
Centaurus Financial
Anaheim,
California
|
-$88K |
GALT Hedge Fund Activity: Q4 2021 in Review
55 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2021, worth a combined $15.2M — down 46% from $28.2M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of GALT and 7 opened new positions — a net loss of 13 holders — while 11 trimmed existing stakes and 15 added.
The largest buyer was Renaissance Technologies, adding an estimated $586K. The largest seller was Ergoteles, exiting entirely with an estimated $529K sold.
- 55 institutional investors held Galectin Therapeutics (GALT) as of Q4 2021, down from 70 in Q3 2021.
- Funds reported $15.2M of Galectin Therapeutics stock for Q4 2021, down 46% quarter-over-quarter.
- 7 funds opened new Galectin Therapeutics positions in Q4 2021 and 20 closed out, a net change of -13 holders.
- The largest Galectin Therapeutics buyer in Q4 2021 was Renaissance Technologies, an estimated $586K added.
- The largest Galectin Therapeutics seller in Q4 2021 was Ergoteles, an estimated $529K sold.
Based on aggregated 13F filings for Q4 2021.